Abstract
The clinical effects of pazufloxacin (PZFX), a newly developed, oral antibacterial agent of new quinolone line, on gynecological infections were examined.
The subjects of 12 patients with gynecological infections were classified into 3 cases with endometritis, 4 cases with salpingitis, 1 case with Bartholin's abscess, 1 case with bartholinitis, 1 case with mastitis, and 2 cases with vaginal stump's abscess. This drug at doses of 100 to 200 mg was p. o. administered two to three times a day. The period of administration ranged from 5 to 7 days.
The clinical effects were effective in all 10 cases except for 2 cases of unable assessment. Bacteriologically, 1 strain of Enterobacter aerogenes was isolated from 1 case, but hardly eliminated after administration of the drug, and Corynebacterium sp. appeared as replacing bacteria. Also, as adverse reactions attributable to this drug, stomach discomfort and diarrhea were observed in 1 case. No abnormal finding in laboratory test was observed.
